Marker Therapeutics Inc (MRKR)

[LaJollaCA]

Maybe you should ask Rogerthat1 so he/she could type up another email for you.


Rogerthat1 Monday, 02/15/16 10:51:16 AM
Re: Rogerthat1 post# 13093
Post #
13104
of 14471 Go
Based on response below from Glynn - it appears IMO that partnership with BP is basically a GO. Why else would they push back their large PII in TNBC with Mayo for Q2 unless they're going to undertake something else of same or greater magnitude? Ie PII trial with BP in Ovarian with inhibitor IMO.

Quote:
Thanks for your support. We expect two Phase II trials to start this quarter – our own Phase II in Triple Negative Breast Cancer and our Phase II in ovarian cancer in combination with a checkpoint inhibitor and a pharma partner. The large Phase II trial in Triple Negative at the Mayo Clinic (and funded by the Department of Defense) will start Q2. As you indicated we had hoped to announce the combination study with the Pharma partner earlier but administrative details and agreements in a three-way collaboration (TPIV-Cancer Institute-Pharma partner) can often take longer than expected. I will announce this as soon as I can with the trial scheduled to start this Q. Despite this we are excited by our progress and the plans for this year.
Best regards
Glynn

Glynn Wilson, Ph.D.
Chairman & CEO
TapImmune Inc.
50 North Laura Street, Suite 2500
Jacksonville, FL 32202
904.516.5436